Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Recruiting
Phase 2
Interventional Study
VHL Pancreatic Neuroendocrine Tumors
Von Hippel-Lindau Disease
Neuroendocrine Tumors
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 12 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 740 (estimated)
- Sponsor
- National Cancer Institute (NCI) · NIH
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Background:
People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect them. This may help them design better future treatment and care for people with VHL disease.
Objecti…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
* INCLUSION CRITIERIA:
1. Participants who have been diagnosed with VHL using the following criteria:
\-- Identification of a heterozygous germline pathogenic variant in VHL by molecular genetic testing.
or
\-- Clinical criteria
2. Participants with at least 1 pancreatic manif…
Contacts